Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.53 |
| ▸ | ACP3 | P15309 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8491974 | 0.86 | TAAR1 (0.61) | TAAR1FFAR4FFAR1ACP3EPHX1 | |
| SCHEMBL365336 | 0.85 | FFAR1 (0.70) | TAAR1FFAR4FFAR1ACP3EPHX1 | |
| SCHEMBL15032898 | 0.85 | ALDH1A1 (0.56) | ALDH1A1FFAR4HDAC8MAPTKDM4E | |
| Benzylacetone SCHEMBL27750721 | 0.85 | ALDH1A1 (0.72) | ALDH1A1FFAR4FFAR1HDAC8 | |
| SCHEMBL31135527 | 0.84 | TAAR1 (0.54) | TAAR1FFAR4FFAR1ACP3EPHX1 | |
| SCHEMBL11242235 | 0.84 | FFAR1 (0.80) | FFAR4FFAR1HDAC1HDAC8 | |
| SCHEMBL24123560 | 0.83 | TAAR1 (0.57) | TAAR1FFAR4FFAR1ACP3EPHX1 | |
| SCHEMBL185922 | 0.83 | TAAR1 (0.62) | TAAR1FFAR4FFAR1ACP3EPHX1 | |
| SCHEMBL30645023 | 0.83 | TAAR1 (0.62) | TAAR1FFAR4FFAR1ACP3EPHX1 | |
| Hydrochloric Acid SCHEMBL30765594 | 0.83 | FFAR1 (0.68) | TAAR1FFAR4FFAR1ACP3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624182-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2483252-B1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-1757582-B1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9090573-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-1553078-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1275635-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1203761-A2 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6211244-B1 | AROMATIC AMINES FOR COMPLEXING CALCIUM | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1996012697-A9 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMA INC (US) | 2000-08-24 | — | — | WO | disclosed |
| EP-0787122-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012697-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| US-4647579-A | Circulation active novel substituted 4-hydroxy-benzopyrans | BAYER AKTIENGESELLSCHAFT (DE) | 1987-03-03 | — | — | US | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| US-4328355-A | ANTIFERTILITY AGENTS | G. D. SEARLE & CO. (US) | 1982-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | NAT1, INMT, ARSA | TAAR1 158/4885ALDH1A1 213/4885FFAR4 1623/4885 |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | TAAR1 361/4885ALDH1A1 3726/4885FFAR4 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.